BLU-222

FDA hands down a partial hold for PhI/II trial of Blueprint’s CDK2 inhibitor
Endpoints
Fri, 02/10/23 - 11:05 am
FDA
Blueprint Medicine
clinical trials
solid tumors
BLU-222